CRA consultant Becky Davis recently presented “GLP-1s: Riding the Wave of Innovative Medications” at Asembia’s AXS25 Summit, which looked at the evolution of the GLP-1 category, and what might be in store for future payer management.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...